CIK 0001680581 · Non-accelerated filer<br>Smaller reporting company
Fulcrum Therapeutics, Inc.
Sign in to watch- Ticker
- FULC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 474839948
- Phone
- 617-651-8851
- Business address
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 83 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-26 | Musso Alan A Chief Financial Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2024-01-26 | Oltmans Curtis Gale Chief Legal Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2024-01-17 | Musso Alan A Chief Financial Officer | Grant or award · Stock Option (right to buy) | +61,822 | 61,822 | ||
| 2023-08-07 | Musso Alan A Chief Financial Officer | Grant or award · Stock Option (right to buy) | +432,800 | 432,800 | ||
| 2023-06-27 | GERAGHTY JAMES A Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-06-27 | Banks Sonja Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-06-27 | Haviland Kate Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-06-27 | Dorton Katina Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2023-06-27 | Ezekowitz Alan Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-06-27 | Gould Robert J Interim President & CEO | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-06-27 | Collins James J. Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2023-05-10 | Tourangeau Greg Principal Accounting Officer | Sale | −210 | $3.31 | $695 | 15,992 |
| 2023-04-26 | Hayes Melvin H. III Chief Operating Officer | Grant or award · Stock Option (right to buy) | +115,000 | 115,000 | ||
| 2023-04-26 | Oltmans Curtis Gale Chief Legal Officer | Grant or award · Stock Option (right to buy) | +127,500 | 127,500 | ||
| 2023-02-09 | Oltmans Curtis Gale Chief Legal Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2023-02-09 | Tourangeau Greg Controller | Grant or award · Stock Option (right to buy) | +16,100 | 16,100 | ||
| 2023-02-09 | Hayes Melvin H. III Chief Operating Officer | Grant or award · Stock Option (right to buy) | +135,000 | 135,000 | ||
| 2023-02-09 | Rajavelu Esther Chief Financial Officer | Grant or award · Stock Option (right to buy) | +160,000 | 160,000 | ||
| 2023-01-20 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Purchase | +1,923,076 | $13.00 | $25.0M | 11,609,704 |
| 2023-01-13 | Gould Robert J Interim President & CEO | Sale | −6,766 | $15.00 | $101K | 499,864 |
Page 4 of 7 · 136 trades